Synapse

← EJC Paediatric Oncology

Papers in EJC Paediatric Oncology

Page 1 · newest first

  1. Identifying gaps and needs in education and career support programs for childhood, adolescent, and young adult cancer survivors: An EU-CAYAS-NET focus group studyEJC Paediatric Oncology · 2026
  2. Early and long-term patency of inferior vena cava patch reconstruction in children with renal tumour thrombusEJC Paediatric Oncology · 2026
  3. Access to innovative therapies outside clinical trials in pediatric oncology: a national real-world analysis of off-label and compassionate use of targeted therapies and immunotherapiesEJC Paediatric Oncology · 2026
  4. Availability, use and challenges of imaging modalities in neuroblastoma: A SIOPEN surveyEJC Paediatric Oncology · 2026
  5. Brachytherapy for localized rhabdomyosarcoma: results from the European paediatric soft tissue sarcoma study group RMS2005 trialEJC Paediatric Oncology · 2026
  6. Social support experiences and unmet needs of grandparents following a grandchild’s cancer diagnosis: A two-year longitudinal mixed-methods study (The GROkids project)EJC Paediatric Oncology · 2026
  7. Body image issues among adolescents and young adult cancer patients and survivors – A literature review from the STRONG AYA ProjectEJC Paediatric Oncology · 2026
  8. European Standard Clinical Practice Recommendations for Children and Adolescents With Non-Rhabdomyosarcoma and Other Rare Soft Tissue Neoplasms: A Joint Epssg and Ern Paedcan ProjectEJC Paediatric Oncology · 2026
  9. Socioeconomic variation in survival from childhood neuroblastoma in northern England: a population-based studyEJC Paediatric Oncology · 2026
  10. Methodological resources to guide the collection of health-related quality of life data in paediatric cancer clinical trials: scoping reviewEJC Paediatric Oncology · 2026
  11. Longitudinal neuropsychological outcomes after pediatric non-CNS cancer diagnosis and the role of neurological complicationsEJC Paediatric Oncology · 2026
  12. Paediatric oncology meets palliative care: A road towards a common languageEJC Paediatric Oncology · 2026
  13. Moesin contributes to the unfavourable prognosis of glioblastoma multiforme possibly by modulating the immune checkpoint molecule B7-H3EJC Paediatric Oncology · 2026
  14. A systematic review of treatments for paediatric patients with relapsed/refractory mature B-cell Non-Hodgkin lymphomaEJC Paediatric Oncology · 2026
  15. Evaluation of treatment outcomes for wilms tumor in children of Viet Nam using a chemotherapy-surgery strategy: Research in a low- and mid-income countryEJC Paediatric Oncology · 2026
  16. Assessing bone marrow involvement in paediatric Non-Hodgkin lymphoma: a comparative analysis of imaging ([18F]FDG PET-CT and WB-DW-MRI) and bone marrow aspiration – a retrospective study.EJC Paediatric Oncology · 2026
  17. Use of antidepressant drugs, alone or in combination with other psychotropic drugs, among five-year childhood cancer survivors in a Nordic setting: A register-based cohort study from the SALiCCS research programmeEJC Paediatric Oncology · 2026
  18. MicroOrganoSphere™ technology to advance drug screening in neuroblastoma precision medicineEJC Paediatric Oncology · 2026
  19. Patient-derived organoid in vitro models for antibody-based immunotherapy in pediatric solid tumorsEJC Paediatric Oncology · 2026
  20. A Phase II trial of intrathecal liposomal cytarabine and chemoimmunotherapy with high-dose methotrexate in children, adolescents and young adults with de-novo mature B-NHLEJC Paediatric Oncology · 2026
  21. Marketing Authorisations with Limited Clinical Evidence: A Review of Small-Scale Cancer Drug StudiesEJC Paediatric Oncology · 2026
  22. The insurance, legal, and financial situation of parents of childhood and adolescent cancer survivors: A systematic reviewEJC Paediatric Oncology · 2026
  23. Information and Support Needs of Childhood, Adolescent, and Young Adult Cancer Survivors (CAYACS) Across Europe and Associations with Patient Activation and Health-Related Quality of Life: Results from the e-QuoL ProjectEJC Paediatric Oncology · 2026
  24. Chronic fatigue among adult, long-term survivors of childhood cancer compared to the general population: The Nor-CAYACS studyEJC Paediatric Oncology · 2026
  25. Ewing’s sarcoma of the head and neck: Outcomes of 102 patients treated at a tertiary cancer centreEJC Paediatric Oncology · 2026
  26. Stereotactic Ablative Radiotherapy Extends Time to Subsequent Systemic Therapy in Pediatric Cancer Patients With Recurrent or Metastatic DiseaseEJC Paediatric Oncology · 2026
  27. Challenges in delineation for Ewing Sarcoma of the chest wall and pelvis: results of a QUARTET – Euro-Ewing Consortium joint workshopEJC Paediatric Oncology · 2026
  28. Contouring and dose extraction of the maxilla, mandible and teeth on head and neck cancer radiotherapy planning scans.EJC Paediatric Oncology · 2026
  29. A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Patients with Relapsed or Refractory Ewing SarcomaEJC Paediatric Oncology · 2026
  30. Current pattern of care in brain and near-brain tumor radiotherapy for infants and young children: A survey on age restrictions, treatment conditions and decision-making within SIOP EuropeEJC Paediatric Oncology · 2026
  31. Simultaneous integrated boost in paediatricsEJC Paediatric Oncology · 2026
  32. Characteristics and outcome of patients with second and subsequent relapse of Wilms tumour - A report from the SIOP Renal Tumour Study GroupEJC Paediatric Oncology · 2026
  33. Modern trends in pediatric radiotherapy utilizationEJC Paediatric Oncology · 2026
  34. Childhood, adolescent and young adult cancer and the prevalence of diagnosed autism or attention deficit hyperactivity disorder: A systematic review and meta-analysisEJC Paediatric Oncology · 2026
  35. Late Effects in Childhood Cancer Survivors: A Global Call to Action Based on the PENTEC InitiativeEJC Paediatric Oncology · 2026
  36. Warburg metabolic states are heterogeneous and frequent in pediatric hematological malignanciesEJC Paediatric Oncology · 2026
  37. Dentofacial side-effects in childhood cancer survivors: the SMILE consortiumEJC Paediatric Oncology · 2026
  38. Non-anaplastic PTCL in children- reviewEJC Paediatric Oncology · 2026
  39. Cushing's Warning: Cushing’s Syndrome as first sign of CNS relapse in pediatric acute lymphoblastic leukemia.EJC Paediatric Oncology · 2026
  40. Towards establishing hippocampal dose constraints for pediatric brain tumor radiotherapy: protocol of the prospective multicentre IPANEMA study (Irradiation in Pediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention)EJC Paediatric Oncology · 2026
  41. Pelvic and para-aortic nodal delineation practices and their applicability in rhabdomyosarcoma – A literature reviewEJC Paediatric Oncology · 2026
  42. Paediatric-Type Follicular Lymphoma: A Distinct Clinicopathologic Entity in Children and Adolescents. A short reviewaEJC Paediatric Oncology · 2026
  43. Challenges of Delivering Bi-Daily General Anaesthetic for Hyperfractionated Accelerated Proton Beam Therapy for High-Risk MedulloblastomaEJC Paediatric Oncology · 2026
  44. Cancer in Childhood, Adolescence, or Young Adulthood and Risk of Congenital Malformations and Chromosomal Abnormalities in Children: A Matched Cohort Study and Descriptive Pooled AnalysisEJC Paediatric Oncology · 2026
  45. Outcomes of palliative radiotherapy and palliative reirradiation in childrenEJC Paediatric Oncology · 2026
  46. Assessment of health-related quality of life with the PedsQL 3.0 Cancer Module in Latvian paediatric oncology patientsEJC Paediatric Oncology · 2026
  47. The interplay of inborn errors of immunity with hematology – Report of the joint focus meeting of ESID, EHA, and SIOPE, Vienna, AustriaSHILAP Revista de lepidopterología · 2026
  48. Impact of disease burden and educational attainment on health-related unemployment among childhood cancer survivors: A mediation analysis within the Nordic SALiCCS research programmeSHILAP Revista de lepidopterología · 2026
  49. Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trialSHILAP Revista de lepidopterología · 2026
  50. Congenital histiocytosis with central nervous system involvement and a novel PTPRJ::RASGRF1 fusionEJC Paediatric Oncology · 2026